Sign In
4 NOV, 2013 - Terumo BCT Acquires GADA Turkey
11/4/2013

Turkish medical products and services distributor provides strategic benefits

 

LAKEWOOD, Colo.—November 4, 2013—Terumo BCT has acquired GADA® Turkey, an exclusive supplier and world-class distributor of blood bank components and equipment to Turkish public and private healthcare facilities. GADA Turkey has been a Terumo BCT distributor to blood banks and hospitals since 2009. The acquisition provides Terumo BCT with a direct relationship with Turkish blood banks and the ability to drive further adoption of critical blood transfusion technologies that can improve the safety and quality of blood in Turkey. The acquisition will also enable hospitals to have expanded access to Terumo BCT's therapeutic aphaeresis technologies.

 

KEY FACTS:

  • Prior to the acquisition, GADA Turkey was a subsidiary of The GADA® Group Holding, a United Kingdom-based, leading pan-European, distributor of specialized medical technology devices and equipment and a provider of health care services supplies and integrated project to public and private facilities.
  • GADA Turkey is active in two major segments: blood technologies and general hospital.
    • The blood technologies segment is composed of three different areas: blood banking, transfusion and therapeutics.
    • The general hospital segment focuses on a wide-choice supply of high technology single-use devices and disposables.

 

KEY QUOTES:

Vincent Gaspar, Senior Vice President and General Manager, EMEA, Terumo BCT

 

"Strategically the GADA Group is a great fit. It is a well-run company with a strong reputation for customer service, quality and collaboration. With this acquisition we will expand our presence in Turkey and the success we have had with our automated collection and therapeutic aphaeresis products. We also intend to introduce Whole Blood Automation and our Mirasol® blood safety products in the Turkish market. We look forward to continuing the high level of support to our customers with field-based resources, and to providing them with direct access to our wide range of products and services."

 

About Terumo BCT:

 

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

 

Principal Terms and Closing:

 

The transaction has been structured as a share purchase and is expected to close in Terumo BCT's fourth fiscal quarter, subject to approval and customary conditions. After the closing, GADA Turkey will be operated as a subsidiary of Terumo BCT Europe, N.V.

 

Special Note:

 

Statements that relate to future results and events are forward-looking statements based on Terumo BCT's and the GADA Group's current expectations. Actual results and events in future periods may differ materially from those expressed or implied by these forward-looking statements because of a number of risks, uncertainties and other factors. Risks, uncertainties and assumptions include the possibility that projected benefits may not materialize as expected; that the transaction may not be timely completed, if at all; that Terumo BCT and the GADA Group are unable to successfully implement the plans, strategies and objectives of management for future operations.